Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Xunfei Healthcare Technology

    • Home
    • Xunfei Healthcare Technology
Company Deals

Jiangxi Rimag Group and Xunfei Healthcare Form Strategic Alliance for Smart Healthcare

Fineline Cube Feb 20, 2025

China-based Jiangxi Rimag Group Co., Ltd (HKG: 2522) announced a strategic alliance with Xunfei Healthcare...

Company Deals

iFlytek’s Subsidiary Xunfei Healthcare Technologies Lists on HKEX, Raises Over HKD 580 Million

Fineline Cube Dec 19, 2024

Xunfei Healthcare Technology Co., Ltd, a subsidiary of China-based information technology company iFlytek Co., Ltd...

Company Deals

iFlytek’s Xunfei Healthcare Passes HKEX Hearing for AI-Powered Medical IPO

Fineline Cube Dec 16, 2024

Xunfei Healthcare Technology Co., Ltd., a subsidiary of China’s leading information technology company iFlytek Co.,...

Recent updates

  • Novo Nordisk semaglutide Alzheimer’s biomarkers fail primary endpoint
  • Acotec V-otter Microcatheter Secures NMPA Approval for TACE Procedures
  • Youjia-Bio Tongee-Medical Nucleic-Acid-Drug Partnership Targets Diabetes
  • Fosun-Pharma FXS0887 ATR-Inhibitor Gets NMPA Phase 1 Nod
  • TransThera Tinengotinib Cholangiocarcinoma Priority Review China
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company Drug

Novo Nordisk semaglutide Alzheimer’s biomarkers fail primary endpoint

Company Medical Device

Acotec V-otter Microcatheter Secures NMPA Approval for TACE Procedures

Company Deals

Youjia-Bio Tongee-Medical Nucleic-Acid-Drug Partnership Targets Diabetes

Company Drug

Fosun-Pharma FXS0887 ATR-Inhibitor Gets NMPA Phase 1 Nod

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.